Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 50 and 85 years old
- People who have been diagnosed with Alzheimer's disease at a mild to moderate stage, based on recognised diagnostic guidelines (NIA-AA 2011 criteria)
- People whose memory and thinking test score (called an MMSE) falls between 14 and 26
- People whose test results show Alzheimer's-related protein deposits (amyloid) in the brain
- People with a clinical dementia rating (CDR) score of 1 or higher, which indicates at least mild dementia
- People who have no medical reasons preventing them from having a PET scan or MRI scan
- People who have a regular caregiver or support person involved in their care
- People who have a study partner who can also sign the consent forms alongside them
- People who have French social security coverage
Who may not be able to join:
- People who have another brain condition (other than Alzheimer's disease) that could be causing dementia
- People who have other health conditions that would prevent safe participation in the study
- People who are already taking part in another research study that could affect the results of this trial
- People who have a pacemaker, an artificial heart valve, any internal magnetic or electronic device, a history of brain or aneurysm surgery, metal fragments in the eyes, brain, or spine, or who experience severe anxiety in enclosed spaces (claustrophobia)
- People who have had a PET scan in the past year as part of a research study
- People who have been diagnosed with cancer within the last 5 years
- People whose brain MRI shows more than 4 tiny bleeds in the brain, a particular type of iron deposit on the brain surface, or signs of a previous large bleed in the brain
- People who regularly use corticosteroid or steroidal anti-inflammatory medications (such as prednisone)
- People who have an autoimmune disease (such as rheumatoid arthritis or lupus), with the exception of psoriasis
- Women who are pregnant or breastfeeding
- People who are under legal guardianship or any other form of legal protection, or who are restricted by a court or government decision
- For people taking part in an optional procedure at the Toulouse centre only: people who are on blood-thinning medication or who have an allergy to xylocaine would not be eligible for that specific optional part of the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Julien DELRIEU, MD_PH, University Hospital of Toulouse
Phone: 05 61 77 70 58
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
number of participants in each group with a clinically significant serious or non-serious AE related to treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.